Other Nrf2 activators such as the thiol-reactive agent oltipraz (OPZ) and NK-252 (1-(5-(furan-2-yl)-1,3,4-oxadiazol-2-yl)-3-(pyridin-2-ylmethyl)urea) significantly attenuated the progression of hepatic fibrosis in a rat model of NASH [3]. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatohepatitis.